Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics. The two companies will work together to ensure the production of Viking’s GLP ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...

Viking Therapeutics inks broad manufacturing pact with CordenPharma to support commercialization of VK2735: San Diego Wednesday, March 12, 2025, 17:00 Hrs [IST] Viking Therapeutic ...

After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Viking Therapeutics stock toppled Tuesday after the biotech company inked a $150 million manufacturing deal for its weight-loss drug, VK2735.